UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

PLoS medicine, 2016-03, Vol.13 (3), p.e1001967-e1001967

2016

Volltextzugriff (PDF)

882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer

Annals of oncology, 2020-09, Vol.31, p.S646-S646

2020

Volltextzugriff (PDF)

Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort

International journal of radiation oncology, biology, physics, 2022-04, Vol.112 (5), p.e10-e11

2022

Volltextzugriff (PDF)

930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors

Annals of oncology, 2021-09, Vol.32, p.S816-S816

2021

Volltextzugriff (PDF)

1064TiP - Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Annals of oncology, 2019-10, Vol.30, p.v433-v434

2019

Volltextzugriff (PDF)

Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Annals of oncology, 2019-10, Vol.30, p.v433-v434

2019

Volltextzugriff (PDF)

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of oncology, 2023-11, Vol.34, p.S1586

2023

Volltextzugriff (PDF)

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of oncology, 2023-10, Vol.34, p.S1276-S1277

2023

Volltextzugriff (PDF)

40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A1-A1

2021

Volltextzugriff (PDF)

1064TiPPhase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

Annals of oncology, 2021-09, Vol.32, p.S726-S727

2021

Volltextzugriff (PDF)

O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results

International journal of gynecological cancer, 2021-11, Vol.31 (Suppl 4), p.A7-A8

2021

Volltextzugriff (PDF)

EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

International journal of gynecological cancer, 2021-11, Vol.31 (Suppl 4), p.A129-A130

2021

Volltextzugriff (PDF)

5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations

ESMO open, 2023-03, Vol.8 (1), p.100971, Article 100971

2023

Volltextzugriff (PDF)

An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN)

Annals of oncology, 2017-09, Vol.28, p.v628-v629

2017

Volltextzugriff (PDF)

Nodules thyroïdiens: à propos de 230 cas opérés au CHU de Conakry

Revue Africaine de Chirurgie et Spécialités, 2011-05, Vol.4 (7)

2011

Volltextzugriff (PDF)

Adaptations of market garden producers to climate change in southern Mali

GeoJournal, 2022-12, Vol.87 (6), p.5413-5424

Soumaoro, Tiémoko

2022

Volltextzugriff (PDF)

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Journal of clinical oncology, 2019-11, Vol.37 (31), p.2825-2834

2019

Volltextzugriff (PDF)

HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study

Journal of antimicrobial chemotherapy, 2022-10, Vol.77 (11), p.3093-3101

2022

Volltextzugriff (PDF)

Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer

Clinical cancer research, 2004-12, Vol.10 (24), p.8465-8471

2004

Volltextzugriff (PDF)

Anxiety and depression among HIV patients of the infectious disease department of Conakry University Hospital in 2018

Epidemiology and infection, 2020-01, Vol.148, p.e8-e8, Article e8

2020

Volltextzugriff (PDF)

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

Cancer science, 2022-08, Vol.113 (8), p.2788-2797

2022

Volltextzugriff (PDF)

Progress towards elimination of onchocerciasis transmission in Mali: A “pre-stop MDA” survey in 18 transmission zones

PLoS neglected tropical diseases, 2023-11, Vol.17 (11), p.e0011632-e0011632

2023

Volltextzugriff (PDF)

Health Risk Assessment of Heavy Metal Accumulation in Broiler Chickens and Heavy Metal Removal in Drinking Water using Moringa Oleifera Seeds in Lomé, Togo

Journal of health & pollution, 2021-09, Vol.11 (31), p.210911-15

2021

Volltextzugriff (PDF)

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

CPT: pharmacometrics and systems pharmacology, 2023-09, Vol.12 (9), p.1262-1273

2023

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer

Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort

930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors

1064TiP - Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

1064TiPPhase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results

EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations

An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN)

Nodules thyroïdiens: à propos de 230 cas opérés au CHU de Conakry

Adaptations of market garden producers to climate change in southern Mali

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study

Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer

Anxiety and depression among HIV patients of the infectious disease department of Conakry University Hospital in 2018

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

Progress towards elimination of onchocerciasis transmission in Mali: A “pre-stop MDA” survey in 18 transmission zones

Health Risk Assessment of Heavy Metal Accumulation in Broiler Chickens and Heavy Metal Removal in Drinking Water using Moringa Oleifera Seeds in Lomé, Togo

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Suchergebnisse filtern